Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 20 | ||
By: PR Newswire Association LLC. - 19 Sep 2014 | Back to overview list |
|
SAN FRANCISCO, Sept. 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The preclinical research candidates were created using Nektar's small molecule polymer medicinal chemistry platform. The analgesic properties of kappa receptor agonism are well described in the medical literature.1,2 Kappa opioid receptors are expressed in the peripheral nervous system as well as in the central nervous system (CNS), and activation of these receptors at both sites has been shown to result in a reduction in pain and inflammation in a wide range of preclinical models.1,4 However, the therapeutic use of kappa receptor agonists has been limited because activation of these receptors in the CNS is associated with significant dysphoria and other unwanted side effects (i.e., anxiety, restlessness and fidgeting).3 "We are encouraged by the results of our research, which shows that we can achieve efficacy through the peripheral activation of the kappa opioid receptor, while at the same time reducing the side effects observed with centrally-acting kappa agonist molecules," said Stephen K. Doberstein, Ph.D., senior vice president and chief scientific officer of Nektar Therapeutics. "With this research, we are continuing to capitalize on the ability of our small molecule polymer medicinal chemistry platform to create new peripherally-acting molecules that could address different pain conditions." Results presented showed that a series of novel, oral, peripherally-acting kappa agonist molecules demonstrated a 15-fold improved therapeutic index (separation between efficacy and CNS-mediated side effects) compared with kappa agonist molecules that were not peripherally selective. The preclinical data is being presented today at the American Academy of Pain Management Annual Meeting (Choi IY, et al. Characterization of novel, oral peripherally-acting kappa agonists in preclinical models). About Nektar Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com. MOVANTIK is a trademark of the AstraZeneca group of companies. Cautionary Note Regarding Forward-Looking Statements 1. Machelska H, et al. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther. 1999;290(1): 354-61. 2. Hope PJ, Fleetwood-Walker SM, Mitchell R. Distinct antinociceptive actions mediated by different opioid receptors in the region of lamina I and laminae III-V of the dorsal horn of the rat. Br J Pharmacol. 1990101(2): 477-83. 3. Vanderah TW, et al. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol. 2008. 583(1):62-72. 4. Millan MJ, et al. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain. 1988;35(3):299-312. Contact: Media SOURCE Nektar Therapeutics |
||
|
||
Copyright 2014 PR Newswire Association LLC. | Back to overview list |